RadNuc: A graphical user interface to deliver dose rate patterns encountered in nuclear medicine with a 137Cs irradiator

NCRP Report No. 160, 2009 Thurston, 2010, NCRP report no. 160: ionizing radiation exposure of the population of the United States, Phys Med Biol, 55, 6327, 10.1088/0031-9155/55/20/6327 NCRP Report No. 64, 1980 Testa, 1973, The response of mouse haemopoietic colony formers to acute or continuous gamma irradiation, Biomedicine, 19, 183 O'Donoghue, 1989, Dose-rate effects in biologically targeted radiotherapy, Int J Radiat Biol, 56, 745, 10.1080/09553008914551991 Goldenberg, 2006, Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J Clin Oncol, 24, 823, 10.1200/JCO.2005.03.8471 Tubiana, 2006, The debate on the use of linear no threshold for assessing the effects of low doses, J Radiol Prot, 26, 317, 10.1088/0952-4746/26/3/N01 Yamamoto, 1998, Oral administration of tritiated water (HTO) in mouse. III: low dose-rate irradiation and threshold dose-rate for radiation risk, Int J Radiat Biol, 73, 535, 10.1080/095530098142086 Brenner, 2006, Estimating radiation-induced cancer risks at very low doses: rationale for using a linear no-threshold approach, Radiat Environ Bioph, 44, 253, 10.1007/s00411-006-0029-4 Howell, 1997, Design and performance characteristics of an experimental Cs-137 irradiator to simulate internal radionuclide dose rate patterns, J Nucl Med, 38, 727 Olipitz, 2010, Development and characterization of a novel variable low dose-rate irradiator for in vivo mouse studies, Health Phys, 98, 727, 10.1097/HP.0b013e3181d26dc5 Aird, 2001, A purpose-built iodine-125 irradiation plaque for low dose rate low energy irradiation of cell lines in vitro, Br J Radiol, 74, 56, 10.1259/bjr.74.877.740056 Zablotska, 2004, Analysis of mortality among Canadian nuclear power industry workers after chronic low-dose exposure to ionizing radiation, Radiat Res, 161, 633, 10.1667/RR3170 Rao, 1993, Time dose fractionation in radioimmunotherapy: implications for selecting radionuclides, J Nucl Med, 34, 1801 Howell, 1994, Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides, J Nucl Med, 35, 1861 Jones, 1982, The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man, J Nucl Med, 23, 613 Hays, 2002, MIRD dose estimate report no. 19: radiation absorbed dose estimates from 18F-FDG, J Nucl Med, 43, 210 Dillehay LE and Williams JR. Radiobiology of dose-rate patterns achievable in radioimmunoglobulin therapy. Frontiers of radiation therapy and oncology 1990;24:96–103; discussion 21–2. Witzig, 1999, Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma, J Clin Oncol, 17, 3793, 10.1200/JCO.1999.17.12.3793 Witzig, 2002, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma, J Clin Oncol, 20, 3262, 10.1200/JCO.2002.11.017 Wiseman, 2003, Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials, J Nucl Med, 44, 465 Wiseman, 2001, Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, Crit Rev Oncol Hematol, 39, 181, 10.1016/S1040-8428(01)00107-X Fowler, 1990, Radiobiological aspects of low dose rates in radioimmunotherapy, Int J Radiat Oncol Biol Phys, 18, 1261, 10.1016/0360-3016(90)90467-X Mitchell, 2002, Effects of exposure to low-dose-rate 60Co gamma rays on human tumor cells in vitro, Radiat Res, 158, 311, 10.1667/0033-7587(2002)158[0311:EOETLD]2.0.CO;2 Howell, 1991, The question of relative biological effectiveness and quality factor for Auger emitters incorporated into proliferating mammalian cells, Radiat Res, 128, 282, 10.2307/3578051